SynKIR-110

Verismo SynKIR-110 Shows Phase 1 Safety in Solid Tumors

PHILADELPHIA, April 20, 2026 Verismo Therapeutics has reported promising initial Phase 1 clinical data from its STAR-101 trial, evaluating...

By cGxPwire Editor
April 21, 2026

Bio-Pharma

Verismo Therapeutics Unveils Promising CAR T Advances for Solid Tumors at SITC 2025

Philadelphia, November 10, 2025 — Verismo Therapeutics, a clinical-stage biotechnology company pioneering KIR-CAR T cell therapies, presented compelling preclinical...

By cGxPwire Editor
November 11, 2025

Bio-Pharma

Verismo Partners with Miltenyi Biotec to Advance KIR-CAR Clinical Programs

Philadelphia, September 25, 2025 – Verismo Therapeutics, a clinical-stage biotechnology company specializing in KIR-CAR T cell therapies, has announced...